Kala Pharmaceuticals, Inc. (KALA) insider have most recently took part in a trading activity. On Jan 12, 2018 Orbimed Advisors Llc, 10% Owner bought 240,484 shares having total worth of $3,193,628 at the price of $13.28 per share, following the transaction a total of 2,692,715 shares owned by Orbimed Advisors Llc. Before this latest buy, Orbimed Advisors Llc purchased KALA at 1 other times during the past twelve months, for a total investment of $47.9M at an average of $15 per share.
Furthermore, over the past 12 months , the stock was traded 8 times by insiders. an employee of the company was the buyer in 8 instances.
Shares of Kala Pharmaceuticals, Inc. (KALA) traded down 1.92% on Jan 4, 2018, hitting $17.33. 150,584 shares of the company’s stock traded hands. Kala Pharmaceuticals, Inc. has a 52 week low of $13.68 and a 52 week high of $26.53. The company’s market cap is $0 million.
Kala Pharmaceuticals, Inc. (KALA) last announced its earnings results on Nov 7, 2017. The company reported -0.56 earnings per share (EPS) for the quarter, lower than the consensus estimate of -0.36 by $0.2., compared to the consensus estimate of $9 million.
|earnings per share||-0.56|
Latest posts by William White (see all)
- Insider Trading Review: FS Investment Corporation $FSIC - January 13, 2018
- Insider Trader Watch: ENERTOPIA CORP $ENRT - January 13, 2018
- Insider Trading in Focus: Swiss Helvetia Fund, Inc. (The) $SWZ - January 13, 2018